Compare Datadog Inc (DDOG) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Novavax Inc — how do they compare? Datadog Inc trades at $293.23 (market cap $98.31B), while Novavax Inc trades at $12.73 (market cap $1.82B). The key difference: Datadog Inc is far larger — about 54× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 2,936,660). Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Novavax Inc for 59 Days on average.
| DDOG | NVAX | |
|---|---|---|
Market Cap | $98.31B | $1.82B |
Volume | 2,936,660 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $288.15 | $12.56 |
52-Week Low | $102.62 | $6.22 |
Typical Hold Time | 76 Days | 59 Days |
Enterprise Value | $94.61B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $293.26, up 8.08% in the last session, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth from $2.7B in 2024 to $3.4B in 2025. Recent news highlights accelerating AI and enterprise customer expansion, with FBN Securities initiating coverage with an Outperform rating.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and accelerating AI-driven growth, though elevated valuation ratios (P/E 547.6, P/S 25.33) pose risks if growth moderates. Key risks include competitive pressure in cloud monitoring and dependence on enterprise spending cycles. The stock trades above the $276.10 consensus target, suggesting near-term upside may be limited despite bullish sentiment.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
